Showing results (191-200 of 232) with videos related to

Sort By:
Pageof 24
Journal of Alzheimer'S Disease : JAD|December 24, 2025
Serum long-chain omega-3 and omega-6 fatty acids differentially predict brain atrophy, white matter hyperintensities, and lacunes in individuals with cerebral small vessel disease with or without Alzheimer's diseaseLeslie M Yedor, Kathryn O Chambers, Maria Moran-Garrido, et al.
Nature Communications|September 21, 2022
Multi-omic brain and behavioral correlates of cell-free fetal DNA methylation in macaque maternal obesity modelsBenjamin I Laufer, Yu Hasegawa, Zhichao Zhang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersSi Won Ryoo, William Z Lin, Myuri Ruthirakuhan, et al.
Plos Pathogens|August 31, 2023
A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivoTaha Y Taha, Rahul K Suryawanshi, Irene P Chen, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particlesAbdullah M Syed, Alison Ciling, Mir M Khalid, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivoPriyadarshini Jaishankar, Galen J Correy, Yusuke Matsui, et al.
The Journal of Hospital Infection|October 13, 2022
Factors affecting turnaround time of SARS-CoV-2 sequencing for inpatient infection prevention and control decision making: analysis of data from the COG-UK HOCI studyH Colton, M D Parker, O Stirrup, et al.
Journal of Medicinal Chemistry|December 17, 2025
Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In VivoPriyadarshini Jaishankar, Galen J Correy, Yusuke Matsui, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 1, 2026
Repurposing drug screen for the identification of helicase inhibitors from viruses of pandemic concernNicole L Inniss, Margarita Rzhetskaya, Ryan P Kich, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2022
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particlesAbdullah M Syed, Alison Ciling, Taha Y Taha, et al.
Pageof 24